Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Tax Provisions (2023 - 2025)

Entrada Therapeutics has reported Tax Provisions over the past 3 years, most recently at $68000.0 for Q4 2025.

  • Quarterly results put Tax Provisions at $68000.0 for Q4 2025, up 103.78% from a year ago — trailing twelve months through Dec 2025 was $968000.0 (up 8.89% YoY), and the annual figure for FY2025 was $900000.0, changed 0.0%.
  • Tax Provisions for Q4 2025 was $68000.0 at Entrada Therapeutics, down from $700000.0 in the prior quarter.
  • Over the last five years, Tax Provisions for TRDA hit a ceiling of $18.7 million in Q4 2023 and a floor of -$17.4 million in Q3 2023.
  • Median Tax Provisions over the past 3 years was $700000.0 (2025), compared with a mean of $1.9 million.
  • Biggest five-year swings in Tax Provisions: crashed 109.6% in 2024 and later soared 136.84% in 2025.
  • Entrada Therapeutics' Tax Provisions stood at $18.7 million in 2023, then crashed by 109.6% to -$1.8 million in 2024, then skyrocketed by 103.78% to $68000.0 in 2025.
  • The last three reported values for Tax Provisions were $68000.0 (Q4 2025), $700000.0 (Q3 2025), and $200000.0 (Q2 2025) per Business Quant data.